Timeline
2019
2020
- Langen Junior Science Award
- WHO Declares Pandemic
- Paul Ehrlich and Ludwig Darmstaedter Prize
- Supply Bottleneck for Pneumococcal Vaccines
- Blood Donation Remains Possible
- Convalescent Plasma: First Clinical Trial
- COVID-19 Vaccines: First Clinical Trial
- Marketing Authorisation of Gene Therapy
- COVID-19 Vaccines: Second Clinical Trial Approved
- German Presidency of the EU Council
- COVID-19 Vaccines: Two Clinical Trials Approved
- Another Clinical Trial Approved
- Start of Two Rolling Review Procedures
- Allergen Products: European Standards
- Allergen Product: First European Marketing Authorisation
- COVID-19 Peptide Vaccine: First Clinical Trial
- COVID-19 Vaccine: Third Rolling Review Procedure
- Validation of COVID-19 Rapid Tests
- First Marketing Authorisation of a COVID-19 Vaccine
- SafeVac App Available
On 8 September 2020, the Paul-Ehrlich-Institut approves a phase II clinical trial for a vector vaccine candidate from Janssen in Germany, which will also be conducted in parallel in Spain and the Netherlands. This is followed on 9 September 2020 by the approval of a phase II/III clinical trial for the mRNA vaccine candidate from BioNTech; this relates to the German part of a global study being carried out in around 120 study centres.